STOCK TITAN

Codexis to Participate in Piper Sandler 38th Annual Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Codexis (CDXS) will participate in the Piper Sandler 38th Annual Healthcare Conference, scheduled for December 1–3, 2026, in New York City. Management will join a fireside chat on December 2 at 3:00 p.m. ET.

A live webcast will be available on the company’s investor relations website, with a replay available for 90 days after the event.

Loading...
Loading translation...

Key Terms

oligonucleotide, rnai, sirna
3 terms
oligonucleotide medical
"traditional solid phase organic synthesis of oligonucleotide manufacturing"
A short chain of DNA or RNA molecules used to target, detect, or change specific genetic messages inside cells; think of it as a tiny, programmable instruction or zip code that can find and bind one exact genetic sentence. Investors care because oligonucleotides are the active ingredient in a growing class of precision therapies and diagnostics, so their success, manufacturing cost, and regulatory approval can directly affect a company's value and future revenue.
rnai medical
"address the rapidly growing demand for RNAi therapeutics"
RNAi, short for RNA interference, is a natural cellular process that acts like a mute button for specific genes by using small RNA molecules to stop a target gene from producing its protein. For investors, RNAi matters because it is the underlying mechanism behind a class of precision medicines that can silence disease-causing genes, offering high potential returns but also scientific, regulatory and manufacturing risks unique to novel drug platforms.
sirna medical
"stereoisomer control of siRNA"
Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

REDWOOD CITY, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Piper Sandler 38th Annual Healthcare Conference, being held December 1-3, 2026, in New York, New York.

Management will participate in a fireside chat on Wednesday, December 2, 2026, at 3:00 pm ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website at https://ir.codexis.com. A replay will be archived for 90 days following the event.

About Codexis

Codexis® is a leading provider of high-performance enzymatic solutions for efficient and scalable therapeutics manufacturing. The company is currently developing its proprietary ECO Synthesis® Manufacturing Platform, an aqueous enzymatic process that may offer a scalable alternative to traditional solid phase organic synthesis of oligonucleotide manufacturing. Initially, Codexis is applying its technology to address the rapidly growing demand for RNAi therapeutics. Codexis’ unique enzymes can drive improvements such as higher yields, increased purity, reduced energy usage and waste generation, stereoisomer control of siRNA, and improved overall capacity in manufacturing at substantially lower capital requirements, all of which may lead to greater efficiency and reduced costs. In addition, the company supplies high-performance enzymes through its BioCatalysis business that are used in the manufacture of multiple commercially available small molecule therapeutics. For additional information, please visit https://www.codexis.com.  

For More Information
Investor Contact
Georgia Erbez
(650) 421-8100
ir@codexis.com


Keep reading